Trial Profile
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Dasatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 14 Feb 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 31 Aug 2023 Planned End Date changed from 1 Dec 2031 to 7 Dec 2029.
- 09 Jun 2023 Planned End Date changed from 15 May 2023 to 1 Dec 2031.